60 years) patients (p = 0.039). Toxicity differences in all other scales were not significant. Between older (> 60 years) and midaged patients (50-60 years) no significant differences in toxicity were found. This was also true for the comparison between young (< 50 years) versus midaged patient groups (50-60 years). Conclusion The treatment concept of BCT for breast cancer is generally well tolerated. The toxicity-measurement with the new topographic module is feasible. Not modified standard treatment for BC should be performed in elderly women."/>
Skip to main content

Table 1 Tumor characteristics

From: Is standard breast-conserving therapy (BCT) in elderly breast cancer patients justified? A prospective measurement of acute toxicity according CTC-classification

Variable N Valid Percentage
T-Stage
according UICC
  
   pT1 66 60.6
   pT2 38 34.8
   pT3 1 0.9
   Tis 4 3.7
N-Stage
according UICC
  
   pN0+cN0 68+3 65.1
   pN1a 7 6.4
   pN1bi 12 11.0
   pN1bii 5 4.6
   pN1biii 11 10.1
   pN1biv 2 1.8
   pN2 1 0.9
Grading   
   G1 6 5.5
   G2 55 50.5
   G3 34 31.2
Unknown 14 12.8
Total 109 100